- Home
- MBC vs LTGO Comparison
MBC vs LTGO Comparison
Compare MBC & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBC | LTGO |
|---|---|---|
| Founded | 1954 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2022 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MBC | LTGO |
|---|---|---|
| Price | $9.26 | $20.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 661.1K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,734,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $6.61 | $17.22 |
| 52 Week High | $14.22 | $20.50 |
Technical Indicators
Market Signals| Indicator | MBC | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | N/A |
| Support Level | $7.78 | N/A |
| Resistance Level | $9.55 | N/A |
| Average True Range (ATR) | 0.45 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 83.23 | 0.00 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.